Brokerages Set Novartis (NVS) Price Target at $85.39

Novartis (NYSE:NVS) has received an average recommendation of “Hold” from the thirteen brokerages that are currently covering the stock, Marketbeat.com reports. Four analysts have rated the stock with a sell rating, seven have given a hold rating and one has assigned a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $85.39.

NVS has been the subject of several recent research reports. Nord/LB reiterated a “neutral” rating on shares of Novartis in a research note on Tuesday, January 2nd. JPMorgan Chase reiterated a “neutral” rating on shares of Novartis in a research note on Thursday, January 18th. UBS reiterated a “neutral” rating on shares of Novartis in a research note on Monday, January 15th. Finally, Zacks Investment Research cut Novartis from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd.

How to Become a New Pot Stock Millionaire

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NVS. Eagle Asset Management Inc. bought a new stake in Novartis during the third quarter worth $613,000. JPMorgan Chase & Co. lifted its stake in Novartis by 5.0% during the third quarter. JPMorgan Chase & Co. now owns 643,008 shares of the company’s stock worth $54,495,000 after purchasing an additional 30,830 shares during the last quarter. Stifel Financial Corp lifted its stake in Novartis by 5.7% during the third quarter. Stifel Financial Corp now owns 270,251 shares of the company’s stock worth $23,225,000 after purchasing an additional 14,629 shares during the last quarter. Private Advisor Group LLC lifted its stake in Novartis by 11.4% during the third quarter. Private Advisor Group LLC now owns 26,518 shares of the company’s stock worth $2,267,000 after purchasing an additional 2,724 shares during the last quarter. Finally, Synovus Financial Corp lifted its stake in Novartis by 3.5% during the third quarter. Synovus Financial Corp now owns 40,362 shares of the company’s stock worth $3,469,000 after purchasing an additional 1,347 shares during the last quarter. Hedge funds and other institutional investors own 10.76% of the company’s stock.

Shares of NVS stock opened at $80.20 on Thursday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.21 and a quick ratio of 0.91. The company has a market capitalization of $185,859.97, a P/E ratio of 16.60, a P/E/G ratio of 1.80 and a beta of 0.74. Novartis has a 1 year low of $72.67 and a 1 year high of $94.19.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Wednesday, January 24th. The company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.04. The business had revenue of $12.92 billion during the quarter, compared to analysts’ expectations of $12.65 billion. Novartis had a return on equity of 16.03% and a net margin of 15.69%. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.14 earnings per share. analysts predict that Novartis will post 5.33 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This story was reported by Ticker Report and is the property of of Ticker Report. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3341014/brokerages-set-novartis-nvs-price-target-at-85-39.html.

About Novartis

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Etheroll  Trading Up 58.5% Over Last 7 Days
Etheroll Trading Up 58.5% Over Last 7 Days
Contrasting TransMontaigne  & Shell Midstream Partners
Contrasting TransMontaigne & Shell Midstream Partners
Analyzing Superior Uniform Group  & Lululemon Athletica
Analyzing Superior Uniform Group & Lululemon Athletica
Financial Contrast: Aaron’s  and Its Peers
Financial Contrast: Aaron’s and Its Peers
Emerge Energy Services  Receives $13.14 Consensus PT from Brokerages
Emerge Energy Services Receives $13.14 Consensus PT from Brokerages
Zacks: Analysts Anticipate Key Energy Services  to Announce -$1.24 Earnings Per Share
Zacks: Analysts Anticipate Key Energy Services to Announce -$1.24 Earnings Per Share


© 2006-2018 Ticker Report. Google+.